Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
Key Clinical Message We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising...
Gespeichert in:
| Veröffentlicht in: | Clinical case reports 2018-04, Vol.6 (4), p.634-637 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 637 |
|---|---|
| container_issue | 4 |
| container_start_page | 634 |
| container_title | Clinical case reports |
| container_volume | 6 |
| creator | Alderuccio, Juan Pablo Desai, Amrita Yepes, Monica M. Chapman, Jennifer R. Vega, Francisco Lossos, Izidore S. |
| description | Key Clinical Message
We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL.
Breast implant‐associated anaplastic large cell lymphoma (BIA‐ALCL) is a rare peripheral T‐cell lymphoma. BIA‐ALCL presenting with a capsular mass show shorter survival despite implant removal followed by CHOP‐like chemotherapy. We present a patient with BIA‐ALCL successfully treated with frontline brentuximab vedotin. |
| doi_str_mv | 10.1002/ccr3.1382 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5889253</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2022319615</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3402-69cff60879d39714262371abf4760c9da01798e21167ee9430d9f95644ae8fe13</originalsourceid><addsrcrecordid>eNp1kc9KxDAQxoMoKqsHX0AKnjx0d5K0aXMRZPEfLAiiRwlpmmokbdakq-7NR_AZfRKz7irrQRjIMPPjm5l8CB1gGGIAMlLK0yGmJdlAuwRySIFDtrmW76D9EJ4AAENBcgzbaIdwRhmnsIvuz73rems6nVRed_3szbSySl507XrTJTFiWYY-Me3Uyq7_fP-QIThlZK_rRHYyVkNvVGKlf9Cxq7S1iZ2300fXyj201Ugb9P7qHaC787Pb8WU6ub64Gp9OUkUzICnjqmkYlAWvKS9wRhihBZZVkxUMFK8l4IKXmmDMCq15RqHmDc9ZlkldNhrTATpZ6k5nVatrFQ_x0oqpj8f4uXDSiL-dzjyKB_ci8rLkJKdR4Ggl4N3zTIdePLmZ7-LOggAhFHOG80gdLynlXQheN78TMIiFGWJhhliYEdnD9ZV-yZ-vj8BoCbwaq-f_K4nx-IZ-S34Be2qWig</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2022319615</pqid></control><display><type>article</type><title>Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma</title><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><creator>Alderuccio, Juan Pablo ; Desai, Amrita ; Yepes, Monica M. ; Chapman, Jennifer R. ; Vega, Francisco ; Lossos, Izidore S.</creator><creatorcontrib>Alderuccio, Juan Pablo ; Desai, Amrita ; Yepes, Monica M. ; Chapman, Jennifer R. ; Vega, Francisco ; Lossos, Izidore S.</creatorcontrib><description>Key Clinical Message
We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL.
Breast implant‐associated anaplastic large cell lymphoma (BIA‐ALCL) is a rare peripheral T‐cell lymphoma. BIA‐ALCL presenting with a capsular mass show shorter survival despite implant removal followed by CHOP‐like chemotherapy. We present a patient with BIA‐ALCL successfully treated with frontline brentuximab vedotin.</description><identifier>ISSN: 2050-0904</identifier><identifier>EISSN: 2050-0904</identifier><identifier>DOI: 10.1002/ccr3.1382</identifier><identifier>PMID: 29636930</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Breast implant‐associated anaplastic large‐cell lymphoma and brentuximab vedotin ; Case Report ; Case Reports ; Immunotherapy ; Monoclonal antibodies ; non‐Hodgkin's lymphoma ; Targeted cancer therapy</subject><ispartof>Clinical case reports, 2018-04, Vol.6 (4), p.634-637</ispartof><rights>2018 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3402-69cff60879d39714262371abf4760c9da01798e21167ee9430d9f95644ae8fe13</citedby><cites>FETCH-LOGICAL-c3402-69cff60879d39714262371abf4760c9da01798e21167ee9430d9f95644ae8fe13</cites><orcidid>0000-0002-2690-3377</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889253/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889253/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,1412,11543,27905,27906,45555,45556,46033,46457,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29636930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alderuccio, Juan Pablo</creatorcontrib><creatorcontrib>Desai, Amrita</creatorcontrib><creatorcontrib>Yepes, Monica M.</creatorcontrib><creatorcontrib>Chapman, Jennifer R.</creatorcontrib><creatorcontrib>Vega, Francisco</creatorcontrib><creatorcontrib>Lossos, Izidore S.</creatorcontrib><title>Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma</title><title>Clinical case reports</title><addtitle>Clin Case Rep</addtitle><description>Key Clinical Message
We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL.
Breast implant‐associated anaplastic large cell lymphoma (BIA‐ALCL) is a rare peripheral T‐cell lymphoma. BIA‐ALCL presenting with a capsular mass show shorter survival despite implant removal followed by CHOP‐like chemotherapy. We present a patient with BIA‐ALCL successfully treated with frontline brentuximab vedotin.</description><subject>Breast implant‐associated anaplastic large‐cell lymphoma and brentuximab vedotin</subject><subject>Case Report</subject><subject>Case Reports</subject><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>non‐Hodgkin's lymphoma</subject><subject>Targeted cancer therapy</subject><issn>2050-0904</issn><issn>2050-0904</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kc9KxDAQxoMoKqsHX0AKnjx0d5K0aXMRZPEfLAiiRwlpmmokbdakq-7NR_AZfRKz7irrQRjIMPPjm5l8CB1gGGIAMlLK0yGmJdlAuwRySIFDtrmW76D9EJ4AAENBcgzbaIdwRhmnsIvuz73rems6nVRed_3szbSySl507XrTJTFiWYY-Me3Uyq7_fP-QIThlZK_rRHYyVkNvVGKlf9Cxq7S1iZ2300fXyj201Ugb9P7qHaC787Pb8WU6ub64Gp9OUkUzICnjqmkYlAWvKS9wRhihBZZVkxUMFK8l4IKXmmDMCq15RqHmDc9ZlkldNhrTATpZ6k5nVatrFQ_x0oqpj8f4uXDSiL-dzjyKB_ci8rLkJKdR4Ggl4N3zTIdePLmZ7-LOggAhFHOG80gdLynlXQheN78TMIiFGWJhhliYEdnD9ZV-yZ-vj8BoCbwaq-f_K4nx-IZ-S34Be2qWig</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Alderuccio, Juan Pablo</creator><creator>Desai, Amrita</creator><creator>Yepes, Monica M.</creator><creator>Chapman, Jennifer R.</creator><creator>Vega, Francisco</creator><creator>Lossos, Izidore S.</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2690-3377</orcidid></search><sort><creationdate>201804</creationdate><title>Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma</title><author>Alderuccio, Juan Pablo ; Desai, Amrita ; Yepes, Monica M. ; Chapman, Jennifer R. ; Vega, Francisco ; Lossos, Izidore S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3402-69cff60879d39714262371abf4760c9da01798e21167ee9430d9f95644ae8fe13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Breast implant‐associated anaplastic large‐cell lymphoma and brentuximab vedotin</topic><topic>Case Report</topic><topic>Case Reports</topic><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>non‐Hodgkin's lymphoma</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alderuccio, Juan Pablo</creatorcontrib><creatorcontrib>Desai, Amrita</creatorcontrib><creatorcontrib>Yepes, Monica M.</creatorcontrib><creatorcontrib>Chapman, Jennifer R.</creatorcontrib><creatorcontrib>Vega, Francisco</creatorcontrib><creatorcontrib>Lossos, Izidore S.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alderuccio, Juan Pablo</au><au>Desai, Amrita</au><au>Yepes, Monica M.</au><au>Chapman, Jennifer R.</au><au>Vega, Francisco</au><au>Lossos, Izidore S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma</atitle><jtitle>Clinical case reports</jtitle><addtitle>Clin Case Rep</addtitle><date>2018-04</date><risdate>2018</risdate><volume>6</volume><issue>4</issue><spage>634</spage><epage>637</epage><pages>634-637</pages><issn>2050-0904</issn><eissn>2050-0904</eissn><abstract>Key Clinical Message
We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL.
Breast implant‐associated anaplastic large cell lymphoma (BIA‐ALCL) is a rare peripheral T‐cell lymphoma. BIA‐ALCL presenting with a capsular mass show shorter survival despite implant removal followed by CHOP‐like chemotherapy. We present a patient with BIA‐ALCL successfully treated with frontline brentuximab vedotin.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>29636930</pmid><doi>10.1002/ccr3.1382</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-2690-3377</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2050-0904 |
| ispartof | Clinical case reports, 2018-04, Vol.6 (4), p.634-637 |
| issn | 2050-0904 2050-0904 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5889253 |
| source | DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Online Library Open Access; PubMed Central |
| subjects | Breast implant‐associated anaplastic large‐cell lymphoma and brentuximab vedotin Case Report Case Reports Immunotherapy Monoclonal antibodies non‐Hodgkin's lymphoma Targeted cancer therapy |
| title | Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T06%3A06%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frontline%20brentuximab%20vedotin%20in%20breast%20implant%E2%80%90associated%20anaplastic%20large%E2%80%90cell%20lymphoma&rft.jtitle=Clinical%20case%20reports&rft.au=Alderuccio,%20Juan%20Pablo&rft.date=2018-04&rft.volume=6&rft.issue=4&rft.spage=634&rft.epage=637&rft.pages=634-637&rft.issn=2050-0904&rft.eissn=2050-0904&rft_id=info:doi/10.1002/ccr3.1382&rft_dat=%3Cproquest_pubme%3E2022319615%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2022319615&rft_id=info:pmid/29636930&rfr_iscdi=true |